Biocon, an Indian biopharmaceutical company, has announced its collaboration with Libbs Farmaceutica, a Brazilian pharmaceutical company, to launch generic medications in Brazil.
The collaboration between Biocon Pharma, a wholly-owned subsidiary of Biocon, and Libbs Farmaceutica marks the entry of Biocon’s generic formulations into Latin America.
The partnership also builds upon a successful association with Libbs, which started in 2017 to launch generic Trastuzumab in Brazil, according to Express Pharma.
As part of the collaboration, Biocon Pharma will be responsible for drug development and manufacturing. Libbs will use its expertise and reach in Brazil to import, distribute and sell the generic drugs, subject to approvals from ANVISA. (Agência Nacional de Vigilância Sanitária) – the Brazilian Health Regulatory Agency.
CEO and Managing Director of Biocon Siddharth Mittal said, “Expanding our association with Libbs Farmaceutica, a trusted partner, to our generic formulations, will help us establish a firm footing in Latin America, starting with Brazil.”
Abhijit Zutshi, Commercial Head, Global Generics and Sr. Vice President – Marketing at Biocon, said, “The partnership with Libbs further builds on Biocon’s ability to forward integrate its portfolio of complex and differentiated APIs into finished dosages.”
Executive President of Libbs Alcebíades de Mendonça Athayde Junior said, “We are very happy with this partnership that is going to make a difference in our patients’ lives.”
“We started with Biocon Biologics years ago, and we were very successful: our Trastuzumab became a leader in the private market, a milestone for our company,” he added. The news was published on Monday on Express Pharma – India’s leading business news magazine for the pharmaceutical industry.
